Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.43 |
| ▸ | IDH1 | O75874 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 2/20 | 0.38 |
| ▸ | MC3R | P41968 | 2/20 | 0.38 |
| ▸ | MC1R | Q01726 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7331796 | 1.00 | NAAA (0.43) | NAAAIDH1ALDH1A1NPC1RAB9A | |
| SCHEMBL7405405 | 0.97 | IDH1 (0.43) | NAAAIDH1ALDH1A1NPC1RAB9A | |
| SCHEMBL7405402 | 0.97 | IDH1 (0.43) | NAAAIDH1ALDH1A1NPC1RAB9A | |
| SCHEMBL2073646 | 0.96 | IDH1 (0.44) | NAAAIDH1ALDH1A1NPC1RAB9A | |
| SCHEMBL16586003 | 0.96 | IDH1 (0.44) | NAAAIDH1ALDH1A1NPC1RAB9A | |
| SCHEMBL15873097 | 0.95 | NAAA (0.44) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL292406 | 0.95 | NAAA (0.44) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL292405 | 0.95 | NAAA (0.44) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL4610287 | 0.90 | NAAA (0.41) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL6034432 | 0.90 | NAAA (0.41) | NAAAIDH1ALDH1A1PPARAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363119-A1 | PROTEASOME INHIBITORS | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION | 2021-11-25 | — | — | US | disclosed |
| EP-1173170-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1171122-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1173170-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1171122-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6265434-B1 | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. | 2001-07-24 | — | — | US | disclosed |
| US-6248755-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-06-19 | — | — | US | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000059502-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363119-A1 | PROTEASOME INHIBITORS | TP53, CDKN1A, PSME1 | NAAA 3891/4885IDH1 2162/4885ALDH1A1 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.